Artificial lung market seen topping $4.27 billion by 2030

The artificial lung market is projected to grow from $2.88 billion in 2026 to $4.27 billion by 2030, driven by rising respiratory disease cases, critical care demand and broader use of extracorporeal support devices. North America led the market in 2025, while portable and minimally invasive systems are emerging as key growth areas.

Why it matters: - Artificial lungs support patients with severe respiratory failure by oxygenating blood and removing carbon dioxide when natural lung function is compromised. - The market is expanding as hospitals and transplant teams look for life-support options that can bridge patients through critical illness, surgery and transplant procedures. - Growing demand for compact and portable systems points to broader use in emergency, trauma and transport settings.

What happened: - The artificial lung market rose from $2.58 billion in 2025 to an estimated $2.88 billion in 2026. - The Business Research Company forecasts the market will reach $4.27 billion by 2030. - The report puts 2025 North America as the largest regional market. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - The 2025-to-2026 expansion reflects an 11.6% compound annual growth rate. - The forecast period through 2030 implies a 10.4% compound annual growth rate. - Growth has been driven by more acute respiratory failure cases, earlier use of heart-lung machines in cardiothoracic surgery, higher organ transplant volumes, membrane artificial lung advances and wider use of extracorporeal life support systems. - The company says future growth will also come from stronger demand for critical care life-support devices, more investment in advanced oxygenation membrane materials and broader adoption of minimally invasive extracorporeal support. - Key trends include use in severe respiratory failure, expanded use in complex lung and cardiac transplant procedures, preference for temporary support over transplantation and development of transport-friendly devices. - The report also highlights membrane-based artificial lung technology for more efficient gas exchange and longer support. - In June 2024, the Australian Institute of Health and Welfare reported about 8.5 million Australians had chronic respiratory diseases. - That total equals 34% of the Australian population. - The same report said about 2.8 million Australians had asthma. - The report also said 638,000 Australians had chronic obstructive pulmonary disease. - North America’s lead is tied to advanced healthcare infrastructure, ongoing research and development and high adoption of advanced medical technologies. - The report offers market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report includes a free sample and full report links: Download a free sample and View the full report.

Between the lines: - The forecast suggests artificial lungs are moving from a niche surgical support tool toward a broader critical care platform. - The emphasis on portability and minimally invasive use signals demand for devices that can work outside traditional operating-room settings. - Rising respiratory disease prevalence gives the market a larger addressable patient base, especially as air pollution and climate change continue to pressure public health systems.

What's next: - The market is expected to keep expanding through 2030 as device makers improve oxygenation membranes, portability and transport readiness. - Broader adoption in emergency care, trauma care and transplant support will likely shape product development and clinical use. - Continued growth in respiratory disease prevalence could keep demand for artificial lung devices elevated.